Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

OmniAb, Inc. (OABI) Guidance & Earnings Results

On 2026-08-06 OmniAb, Inc. raised guidance: "Full year 2026 revenue and cash outlook…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

OABIOmniAb, Inc.Follow OABI — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
677.5M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
30 Oct, in 6 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26RaisedFull year 2026 revenue and cash outlook raised · full year
7 May 26RaisedRevenue guidance raised from $25-30M to $28-33M · full year
4 Mar 26RaisedFY2026 revenue $25M-$30M · full year
4 Nov 25LoweredRevenue guidance lowered to $18-22M from prior range · full year
6 Aug 25ReaffirmedFY2025 revenue $20-25M; costs and operating expense $85-90M; cash use lower than 2024; effective tax rate ~0% · full year

OmniAb, Inc. — questions

What guidance did OmniAb, Inc. give?
On 2026-08-06: "Full year 2026 revenue and cash outlook raised"
When does OmniAb, Inc. report earnings?
OmniAb, Inc.'s next earnings report is expected on 2026-10-30.

Every figure on this page comes from OmniAb, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.